Response of HbA1c and Weight against time in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits

Ken Thong¹, Bob Ryder¹, on behalf of the ABCD nationwide exenatide and liraglutide audits contributors

¹Diabetes, City Hospital, Birmingham

The ABCD Nationwide Exenatide and Liraglutide Audits

Dr Marc Evans¹ & Dr Chris Walton² on behalf of the Association of British Clinical Diabetologists Nationwide Audit Contributors

¹?

²Hull Royal Infirmary, Hull, UK

ABCD Nationwide Exenatide and Liraglutide Audits

Dr Bob Ryder¹ and Dr Ken Thong¹ on behalf of the ABCD nationwide exenatide and liraglutide audit contributors

¹City Hospital, Birmingham, UK

The influence of age and metformin treatment status on reported gastrointestinal side effects with liraglutide treatment in type 2 diabetes

K.Y. Thong¹, P Sen Gupta¹, A.D. Blann¹, R.E.J. Ryder¹  on behalf of the ABCD nationwide liraglutide audit contributors

¹City Hospital, Birmingham, UK

The Association of British Clinical Diabetologists nationwide exenatide and liraglutide audits suggest a low incidence of acute pancreatitis. Response to Robson. Incretins and pancreatitis—what happens next? A personal viewpoint

R. E. J. Ryder¹, P. Sen Gupta¹, K. Y. Thong¹ on behalf of the ABCD nationwide exenatide and liraglutide audit contributors

¹City Hospital, Birmingham, UK

Safety and efficacy of liraglutide 1.2mg in patients with mild and moderate renal impairment:the ABCD nationwide liraglutide audit

K.Y. Thong¹,  C. Walton², R.E.J. Ryder¹, on behalf of the ABCD nationwide liraglutide audit contributors

¹City Hospital, Birmingham, UK

²Hull Royal Infirmary, Hull, UK

We at DTN-UK hope that you are managing in the current challenging environment. We have been continuing to work hard this week to ensure ongoing support for clinical teams at this busy time. Many of us are getting pulled away from specialty diabetes work, and so our efforts have been to ensure as much continuity for our patients as possible. Here are some key messages from this week:

Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits

K.Y. Thong, M.L. Cull,  R.E.J. Ryder, C. Walton, on behalf of the ABCD nationwide exenatide and liraglutide audit contributors.

1City Hospital, Birmingham, UK

2Hull Royal Infirmary, Hull, UK

Change in HbA1c, weight and blood pressure in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide once weekly (QW) audit

R M Gifford¹, J Joharatnam², K Darzy², A Helmy³, E McKeever³, E Brennon⁴, R Harper⁴, K Sands⁵, D Barnes⁶, R E Ryder⁷ and K A Adamson¹ on behalf of ABCD Exenatide QW Audit contributors

¹NHS Lothian

²East & North Hertfordshire NHS Trust